WorldPharmaNews
  • Home
  • Business
  • Research
  • Jobs
  • Events
  • Regulatory

Pfizer

PfizerAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.

www.pfizer.com

Filters
List of articles in category Pfizer
Title Published Date
Eliquis® (apixaban) reduced the risk of stroke and demonstrated fewer major bleeding events versus Warfarin 23 February 2014
Pfizer and Merck to collaborate on innovative anti-cancer combination studies 06 February 2014
Pfizer reports fourth-quarter and full-year 2013 results 29 January 2014
Pfizer settles Viagra® patent litigation with Teva 17 December 2013
Pfizer expands clinical trial data access policy and launches data access portal 09 December 2013
Pfizer acquires Polocard, Poland's leading over-the-counter heart attack prevention brand 03 December 2013
Pfizer and GSK to initiate study of novel combination therapy in patients with melanoma 21 November 2013
Pfizer reports third quarter 2013 results 30 October 2013
International Atherosclerosis Society and Pfizer Independent Grants for Learning & Change collaborate on new grant opportunity 03 October 2013
Pfizer to create separate, internal, global Innovative and Value businesses 30 July 2013
Pfizer statement on PhRMA-EFPIA principles for responsible clinical trial data sharing 25 July 2013
Pfizer obtains $2.15 billion settlement from Teva and Sun for infringement of Protonix® patent 12 June 2013
United States Patent & Trademark Office grants Pfizer reissue patent for Celebrex® 05 March 2013
Pfizer and AstraZeneca enter into agreement for over-the-counter Nexium 13 August 2012
Pfizer reports second-quarter 2012 results 31 July 2012
Pfizer reports top-line results of study of Lyrica's effect on male reproduction 23 July 2012
Pfizer provides topline results from Phase 3 study of Torisel® 16 May 2012
Pfizer reports first-quarter 2012 results 01 May 2012
Pfizer's Prevnar 13® shown to be immunogenic in older children and adolescents 12 March 2012
Pfizer acquires Alacer Corp., a leading vitamin supplements company 28 February 2012
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
  • End

Business & Industry

  • Bayer exercised option to obtain full licensing rights for larotrectinib and BAY 2731954 (LOXO-195)
  • Boehringer Ingelheim (Canada) Ltd. and IBM Canada announce first of its kind collaboration to integrate blockchain technology into clinical trials
  • Merz delivers double-digit growth in strategic business areas
  • The Union for International Cancer Control and Pfizer announce new phase of global grants initiative supporting metastatic breast cancer patients
  • Merck to expand US biopharmaceutical R&D facility to advance innovative clinical pipeline

Research & Development

  • Researchers develop reversible antiplatelet therapy to fight clotting, cancer metastasis
  • How Viagra puts a brake on a master growth regulator to treat heart disease
  • Nano drops a million times smaller than a teardrop explodes 19th century theory
  • New insight into cell receptors opens the way for tailored cancer drugs
  • New pill can deliver insulin
  • Simple drug combination creates new neurons from neighboring cells
  • Cannabinoid compounds may inhibit growth of colon cancer cells

Conferences & Events

  • eyeforpharma Barcelona Conference, Expo & Awards 2019
  • SMi presents the 2nd Annual Conference: Injectable Drug Delivery 2019
  • 21st Annual Superbugs & Superdrugs Conference
  • SMi Group announces the 10th Annual RNA Therapeutics Conference
  • Pre-Filled Syringes & Injectable Drug Devices Europe 2018
  • Social Media in the Pharmaceutical Industry Conference 2019
  • Lyophilization USA Conference 2018

Regulatory Affairs

  • FDA takes new steps to adopt more modern technologies for improving the security of the drug supply chain
  • FDA takes action against 17 companies for illegally selling products claiming to treat Alzheimer's disease
  • FDA approves first therapy for the treatment of adult patients with a rare blood clotting disorder
  • FDA approves first generic Advair Diskus
  • FDA approves first treatment for rare blood disease
  1. You are here:  
  2. Home
  3. Pfizer
  4. Pfizer and Lilly announce top-line results from second Phase 3 study of tanezumab in osteoarthritis pain

About

  • Home
  • Advertise
  • Privacy
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • Google+
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2006 - 2017. All Rights Reserved. WORLD PHARMA JOBS | PharmaNews.eu | eHealthNews.eu | (HEALTH IT) SPACE